Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5690520 | Urology | 2017 | 30 Pages |
Abstract
A sequentially applied multimodal treatment strategy can eliminate detectable disease in selected patients with metastatic spread at diagnosis. The end point of undetectable PSA after testosterone recovery should be considered when evaluating new approaches to rapidly set priorities for large-scale testing in early metastatic disease states and to shift the paradigm from palliation to cure.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Matthew J. O'Shaughnessy, Sean M. McBride, Hebert Alberto Vargas, Karim A. Touijer, Michael J. Morris, Daniel C. Danila, Vincent P. Laudone, Bernard H. Bochner, Joel Sheinfeld, Erica S. Dayan, Lawrence P. Bellomo, Daniel D. Sjoberg, Glenn Heller,